Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous neoantigen-specific T lymphocytes GEN-011

A preparation of autologous, personalized, immunogenic and tumor neoantigen-specific T lymphocytes, with potential immunostimulating and antineoplastic activities. Tumor-specific neoantigen targets of autologous CD4+ and/or CD8+ T cells are identified and T cells that target immunogenic and stimulatory neoantigens are expanded ex vivo. Upon administration, the autologous neoantigen-specific T lymphocytes GEN-011 recognize and bind to tumor cells expressing the targeted neoantigens, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the patient's tumor cells.
Synonym:autologous immunogenic neoantigen-specific T cells GEN-011
autologous neoantigen-targeting T cells GEN-011
Code name:GEN 011
GEN-011
GEN011
Search NCI's Drug Dictionary